SEC Form 4 · accession 0000899243-18-021103

Verrica Pharmaceuticals Inc. · VRCA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

10% Owner

Period of report

Jun 19, 2018

Accepted (ET)

Aug 1, 2018 · 9:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001660334

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 19, 2018	C	1,130,679	—	A	1,130,679	I	See Footnote
Common Stock^F1,F2	Jun 19, 2018	C	1,279,733	—	A	2,410,412	I	See Footnote
Common Stock^F2	Jun 19, 2018	P	1,000,000	$15.00	A	3,410,412	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Stock^F1,F2	—	Jun 19, 2018	C	1,937,984	D	—	—	Common Stock	1,130,679	0	I
Series C Preferred Stock^F1,F2	—	Jun 19, 2018	C	2,193,463	D	—	—	Common Stock	1,279,733	0	I

F1Each share of the Issuer's preferred stock is convertible, at any time, at the holder's election, into shares of the Issuer's common stock, has no expiration date and converts into shares upon the closing of the Issuer's initial public offering.
F2The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.